Neoadjuvant Ipilimumab Plus Nivolumab in Melanoma: 5-Year Survival and Biomarker Analysis from the Phase II PRADO-Trial

Investigators demonstrate favorable long-term outcomes for patients with an major pathologic responseand identify interferon-gamma and programmed cell death ligand 1 as promising baseline biomarkers.